120 related articles for article (PubMed ID: 33612089)
21. Usefulness of p16ink4a, ProEX C, and Ki-67 for the diagnosis of glandular dysplasia and adenocarcinoma of the cervix uteri.
Negri G; Bellisano G; Carico E; Faa G; Kasal A; Antoniazzi S; Egarter-Vigl E; Piccin A; Dalla Palma P; Vittadello F
Int J Gynecol Pathol; 2011 Jul; 30(4):407-13. PubMed ID: 21623205
[TBL] [Abstract][Full Text] [Related]
22. Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization?
Kietpeerakool C; Srisomboon J; Prompittayarat W; Kanjanavaha P; Peuwsai R; Dheerakul C
Asian Pac J Cancer Prev; 2006; 7(4):522-4. PubMed ID: 17250421
[TBL] [Abstract][Full Text] [Related]
23. Symposium part 4: Should pathologists diagnose endocervical preneoplastic lesions "less than" adenocarcinoma in situ?: Counterpoint.
Lee KR
Int J Gynecol Pathol; 2003 Jan; 22(1):22-4. PubMed ID: 12496693
[TBL] [Abstract][Full Text] [Related]
24. Endocervical adenocarcinoma in situ (AIS) with ovarian and pulmonary involvement: report of a case and review of the literature suggesting a "seed and soil hypothesis".
Horn LC; Höhn AK; Stark S; Einenkel J; Borte G; Haak A; Siebolts U; Brambs CE
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2061-2069. PubMed ID: 31309301
[TBL] [Abstract][Full Text] [Related]
25. Atypical endocervical glandular cells: accuracy of cytologic diagnosis.
Lee KR; Manna EA; St John T
Diagn Cytopathol; 1995 Oct; 13(3):202-8. PubMed ID: 8575278
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.
Teoh D; Musa F; Salani R; Huh W; Jimenez E
Obstet Gynecol; 2020 Apr; 135(4):869-878. PubMed ID: 32168211
[TBL] [Abstract][Full Text] [Related]
27. Adenocarcinoma in situ of the uterine cervix: Clinical practice guidelines from the Italian society of colposcopy and cervical pathology (SICPCV).
Ciavattini A; Giannella L; Delli Carpini G; Tsiroglou D; Sopracordevole F; Chiossi G; Di Giuseppe J;
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():273-277. PubMed ID: 31352128
[TBL] [Abstract][Full Text] [Related]
28. Nucleolar organiser regions in adenocarcinoma in situ and invasive adenocarcinoma of the cervix.
Darne JF; Polacarz SV; Sheridan E; Anderson D; Ginsberg R; Sharp F
J Clin Pathol; 1990 Aug; 43(8):657-60. PubMed ID: 2401734
[TBL] [Abstract][Full Text] [Related]
29. Two cases of adenocarcinoma in situ arising in lobular endocervical glandular hyperplasia indicating localization of mucin on the cluster surface as an early cytological finding of malignant transformation.
Okuyama R; Hashimoto H; Miura T; Sugita M; Arai M; Tsunoda H; Sasajima Y; Horiuchi H
Diagn Cytopathol; 2017 Sep; 45(9):842-847. PubMed ID: 28449203
[TBL] [Abstract][Full Text] [Related]
30. [Risk stratified management of cervical adenocarcinoma in situ based on cone margin state].
Huang SS; Sui L; Chen LM; Zhang HW; Tao X
Zhonghua Fu Chan Ke Za Zhi; 2021 Sep; 56(9):622-629. PubMed ID: 34547863
[No Abstract] [Full Text] [Related]
31. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
32. Personalized Medicine and Cervical Screening: Development of Individualized Quantitative Risk Assessments for Cervical Adenocarcinoma and Adenocarcinoma in situ.
Jones TE; Onisko A; Austin RM
Acta Cytol; 2021; 65(2):158-164. PubMed ID: 33260179
[TBL] [Abstract][Full Text] [Related]
33. The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri and related lesions. III. Pitfalls in diagnosis.
Pacey F; Ayer B; Greenberg M
Acta Cytol; 1988; 32(3):325-30. PubMed ID: 3376699
[TBL] [Abstract][Full Text] [Related]
34. Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia.
Kawai S; Fujii T; Kukimoto I; Yamada H; Yamamoto N; Kuroda M; Otani S; Ichikawa R; Nishio E; Torii Y; Iwata A
Sci Rep; 2018 May; 8(1):7070. PubMed ID: 29728572
[TBL] [Abstract][Full Text] [Related]
35. Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix.
Lu X; Shiozawa T; Nakayama K; Toki T; Nikaido T; Fujii S
Int J Gynecol Pathol; 1999 Apr; 18(2):109-14. PubMed ID: 10202666
[TBL] [Abstract][Full Text] [Related]
36. Distribution of epithelial-specific antigen in uterine cervix with endocervical glandular dysplasia.
Umezaki K; Sanezumi M; Okada H; Okamura A; Tsubra A; Kanazaki H
Gynecol Oncol; 1997 Sep; 66(3):393-8. PubMed ID: 9299251
[TBL] [Abstract][Full Text] [Related]
37. Papanicolaou smear sensitivity for adenocarcinoma in situ of the cervix. A study of 34 cases.
Lee KR; Minter LJ; Granter SR
Am J Clin Pathol; 1997 Jan; 107(1):30-5. PubMed ID: 8980364
[TBL] [Abstract][Full Text] [Related]
38. Microglandular endocervical hyperplasia and tubal metaplasia: pitfalls in the diagnosis of adenocarcinoma on cervical smears.
Selvaggi SM; Haefner HK
Diagn Cytopathol; 1997 Feb; 16(2):168-73. PubMed ID: 9067112
[TBL] [Abstract][Full Text] [Related]
39. Laminin-5 gamma2 chain immunohistochemistry facilitates the assessment of invasiveness and improves the diagnostic reproducibility of glandular lesions of the cervix uteri.
Negri G; Romano F; Vittadello F; Kasal A; Mazzoleni G; Colombetti V; Egarter-Vigl E
Hum Pathol; 2006 Jun; 37(6):704-10. PubMed ID: 16733211
[TBL] [Abstract][Full Text] [Related]
40. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations.
Negri G; Egarter-Vigl E; Kasal A; Romano F; Haitel A; Mian C
Am J Surg Pathol; 2003 Feb; 27(2):187-93. PubMed ID: 12548164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
